Practical markers used in the diagnosis of endocrine tumors

Advances in Anatomic Pathology

Volumn 11, Issue 4, 2004, Pages 175-189

  Erickson, Lori A ^a   Lloyd, Ricardo V ^a  

^a MAYO CLINIC   (United States)

Author keywords

Chromogranin; Endocrine; Keratin; Neuroendocrine; Synaptophysin

Indexed keywords

CHROMOGRANIN; KERATIN; SYNAPTOPHYSIN; TRANSCRIPTION FACTOR; TUMOR MARKER;

DIFFERENTIAL DIAGNOSIS; ENDOCRINE TUMOR; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; NEUROENDOCRINE TUMOR; REVIEW;

CHROMOGRANINS; DIAGNOSIS, DIFFERENTIAL; ENDOCRINE GLAND NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; KERATINS; NEUROENDOCRINE TUMORS; SYNAPTOPHYSIN; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 16544379490     PISSN: 10724109     EISSN: 15334031     Source Type: Journal    
DOI: 10.1097/01.pap.0000131824.77317.a7     Document Type: Review

References (167)

1. Wilson BS, Lloyd RV. Detection of chromogranin in neuroendocrine cells with a monoclonal antibody. Am J Pathol. 1984;115:458-468. (Pubitemid 14121197)
2. Wiedenmann B, Huttner W. Synaptophysin and chromogranins/secretogranins - widespread constituents of distinct types of neuroendocrine vesicles and new tools in tumor diagnosis. Virchows Archiv B Cell Pathol. 1989;58:95-121. (Pubitemid 20012954)
3. Lloyd R. Overview of neuroendocrine cells and tumors. Endocr Pathol. 1996;7:323-328. (Pubitemid 126715764)
4. Lloyd RV. Practical markers used in the diagnosis of neuroendocrine tumors. Endocr Pathol. 2003;14:293-302.
5. Lloyd RV. Immunohistochemical markers of endocrine/neuroendocrine tumors. J Histotechnology. 1999;77:231-237. (Pubitemid 29441487)
6. Lloyd RV, Mereck T, Schmidt K, et al. Immunohistochemical detection of chromogranin and neuron-specific enolase in pancreatic endocrine neoplasms. Am J Surg Pathol. 1984;8:607-614. (Pubitemid 14055019)
7. Lloyd RV, Sisson JC, Shapiro B, et al. Immunohistochemical localization of epinephrine, norepinephrine, catecholamine-synthesizing enzymes, and chromogranin in neuroendocrine cells and tumors. Am J Pathol. 1986;125:45-54. (Pubitemid 17183757)
8. Tischler AS. Granins for the many, epinephrine for the few (editorial). Endocrine Pathol. 2003;14:1. (Pubitemid 36605678)
9. Elferink LA, Scheller RH. Synaptic vesicle proteins and regulated exocytosis. Prog Brain Res. 1995;105:79-85.
10. Zanner R, Gratzl M, Prinz C. Circle of life of secretory vesicles in gastric enterochromaffin-like cells. Ann NY Acad Sci. 2002;971:389-396. (Pubitemid 35305331)
11. DeLellis R, Tischler A. The dispersed neuroendocrine cell system. In: Kovacs K, Asa S, eds. Functional Endocrine Pathology. Boston: Blackwell; 1998;529-549.
12. Gould V, DeLellis R. The neuroendocrine system. In: Silverberg S, ed. Principles and Practice of Surgical Pathology 2nd ed. New York: Churchill Livingstone; 1990;1981-1995.
13. Moll R, Franke WW, Schiller DL, et al. The catalog of human cytokeratins: pattern of expression in normal epithelia, tumor and culture cells. Cell. 1982;31:11-24. (Pubitemid 13215192)
14. Franke WW, Schiller DL, Moll R, et al. Diversity of cytokeratins: differentiation specific expression of cytokeratin polypeptides in epithelial cells and tissues. J Mol Biol. 1981;153:933-959.
15. Steinert PM, Roop DR. Molecular biology of intermediate filaments. Annu Rev Biochem. 1988;57:593-625.
16. Chu PG, Weiss LM. Keratin expression in human tissues and neoplasms. Histopathology. 2002;40:403-439. (Pubitemid 34535443)
17. Chetty R, Pillay P, Jaichand V. Cytokeratin expression in adrenal phaeochromocytomas and extra-adrenal paragangliomas. J Clin Pathol. 1998;51:477-478. (Pubitemid 28312184)
18. Kimura N, Nakazato Y, Nagura H, et al. Expression of intermediate filaments in neuroendocrine tumors. Arch. Pathol. Lab. 1990;114:506-510. (Pubitemid 20147436)
19. Moran CA, Rush W, Mena H. Primary spinal paragangliomas: a clinicopathologic and immunohistochemical study of 30 cases. Histopathology. 1997;31:167-173. (Pubitemid 27357353)
20. Gyere KA, Morrison AL, Thompson LDR, et al. Cytokeratin subset markers in pituitary adenomas. Mod Pathol. 2001;38:561-566.
21. Nishoka H, Ito H, Haraoka J, et al. Histological changes in the hypofunctional pituitary gland following conventional radiotherapy for adenoma. Histopathology. 2001;38:561-566. (Pubitemid 32863009)
22. Lloyd RV, Scheithauer BW, Kovacs K, et al. The immunophenotype of pituitary adenomas. Endocr Pathology. 1996;7:145-150. (Pubitemid 126715144)
23. Battifora H, Silva EG. The use of antikeratin antibodies in the immunohistochemical distinction between neuroendocrine (Merkel cell) carcinoma of the skin, lymphoma, and oat cell carcinoma. Cancer. 1986;58:1040-1046. (Pubitemid 16046934)
24. Sibley RK, Dehner LP, Rosai J. Primary neuroendocrine (Merkel cell) carcinoma of the skin. Am J Surg Pathol. 1985;9:95-108.
25. Chan JKC, Wenig BM, Tsang WYW, et al. Cytokeratin 20 immunoreactivity distinguishes Merkel cell (primary cutaneous neuroendocrine) carcinomas and salivary gland small cell carcinomas from small cell carcinoma of various sites. Am J Surg Pathol. 1977;21:226-230.
26. Jensen K, Kohler S, Rouse RV. Cytokeratin staining in Merkel cell carcinoma: an immunohistochemical study of cytokeratins 5/6, 7, 17, and 20. Appl Immunohistochem Mol Morphol. 2000;8:310-315.
27. Mietinen M, Clark R, Lehto VP, et al. Intermediate-filament proteins in parathyroid glands and parathyroid adenomas. Arch Pathol Lab Med. 1984;109:986-989.
28. Lin BT, Bosib SM, Mierau GW, et al. Oncocytic adrenocortical neoplasms: a report of seven cases and review of the literature. Am J Surg Pathol. 1998;22:603-614. (Pubitemid 28213748)
29. Chu PG, Weiss LM. Cytokeratin 14 immunoreactivity distinguishes oncocytic tumor from its congeners: an immunohistochemical study of 31 cases. Histopathology. 2001;39:455-462. (Pubitemid 34225165)
30. Hoang MP, Ayala AG, Albores-Saavedra J. Oncocytic adrenocortical carcinoma: a morphologic, immunohistochemical and ultrastructural study of four cases. Mod Pathol. 2002;15:973-978.
31. Chu PG, Wu E, Weiss LM. Cytokeratin 7, and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases. Mod Pathol. 2000;13:962-972.
32. Chu PG, Weiss LM. Cytokeratin 14 expression in epithelial neoplasms: a survey of 435 cases with emphasis on its value in differentiating squamous cell carcinomas from other epithelial neoplasm. Histopathology. 2001;39:9-16. (Pubitemid 32848269)
33. Fonseca E, Nesland JM, Hoie J, et al. Pattern of expression of intermediate cytokeratin filaments in the thyroid gland: an immunohistochemical study of sample and stratified epithelial-type cytokeratin. Virchows Arch. 1997;430:239-245. (Pubitemid 27151935)
34. Cheung CC, Ezzat S, Freeman JL, et al. Immunohistochemical diagnosis of papillary thyroid carcinoma. Mod Pathol. 2001;14:338-342. (Pubitemid 32298919)
35. Baloch ZW, Abraham S. Roberts S, LiVolsi VA. Differential expression of cytokeratins in follicular variant of papillary carcinoma: an immunohistochemical study and its diagnostic utility. Hum Pathol. 1999;30:1166-1171. (Pubitemid 29480884)
36. Sahoo S, Hoda SQ, Rosai J, et al. Cytokeratin 19 immunoreactivity in the diagnosis of papillary thyroid carcinoma: a note of caution. Am J Clin Pathol. 2001;111:696-702. (Pubitemid 34453210)
37. Carcangiu ML, Zampi G, Rosai J. Poorly differentiated ("insular") thyroid carcinoma: A reinterpretation of Lanhans' "wuchernde Struma." Am J Surg Pathol. 1984;8:655-668. (Pubitemid 14068779)
38. Ordonez NG, El-naggar AK, Hickey RC, et al. Anaplastic thyroid carcinoma: Immunocytochemical study of 32 cases. Am J Clin Pathol. 1991;96:15-24.
39. Carcangiu ML, Steeper T, Zampi G, et al. Anaplastic thyroid cancer: A study of 70 cases. Am J Clin Pathol. 1985;83:135-158. (Pubitemid 15128839)
40. DeLellis RA, Shin SJ. Diagnostic Immunohistochemistry of endocrine tumors. In Dabbs DJ, ed. Diagnostic Immunohistochemistry. New York: Churchill Livingston; 2002:209-240.
41. Oliveira AM, Tazelaar HD, Myers JL, et al. Thyroid transcription factor-1 distinguishes metastatic pulmonary from well-differentiated neuroendocrine tumors of other sites. Am J Surg Pathol. 2001;25:815-819. (Pubitemid 32496873)
42. Agoff SN, Lamps LW, Philip AT, et al. Thyroid transcription factor-1 is expressed in exptrapulmonary small cell carcinomas but not in other exptrapulmonary neuroendocrine tumors. Mod Pathol. 2000;13:238-242. (Pubitemid 30207508)
43. Kaufmann O, Dietel M. Expression of thyroid transcription factor-1 in pulmonary and extrapulmonary small cell carcinomas and other neuroendocrine carcinomas of various primary sites. Histopathology. 2000;36:415-420. (Pubitemid 30311623)
44. Cai YC, Banner B, Glickman J, et al. Cytokeratin 7 and 20 and thyroid transcription factor 1 can help distinguish pulmonary from gastrointestinal carcinoid and pancreatic endocrine tumors. Hum Pathol. 2001;32:1087-1093. (Pubitemid 33015669)
45. Sturm N, Rossi G, Lanteujoul S, et al. Expression of thyoid transcription factor-1 in the spectrum of neuroendocrine cell lung proliferations with special interest in carcinoids. Hum Pathol. 2002;33:175-182. (Pubitemid 34298732)
46. Bejarano PA, Nikiforov YE, Swenson ES, et al. Thyroid transcription factor-1, thyroglobulin, cytokeratin 7, and cytokeratin 20 in thyroid neoplasms. Appl Immunohistochem Mol Morphol. 2000;8:189-194.
47. Ros P, Rossi DL, Acebron A, et al. Thyroid-specific gene expression in the multi-step process of thyroid carcinogenesis. Biochimie. 1999;81:389-396.
48. Fabbo D, DiLoreto C, Beltrami CA, et al. Expression of thyroid specific transcription factors TTF-1 and PAX-8 in human thyroid neoplasms. Cancer Res. 1994;54:4744-4749. (Pubitemid 24276506)
49. Lloyd RV, Osamura RY. Transcription factors in normal and neoplastic pituitary tissues. Microsc Res Tech. 1997;39:168-181. (Pubitemid 27475458)
50. Moskaluk CA, Zhang H, Powell SM, et al. Cdx2 protein expression in normal and malignant human tissues: an immunohistochemical survey using microarrays. Mod Pathol. 2003;16:913-919. (Pubitemid 37152021)
51. Barbareschi M, Roldo C, Zamboni G, et al. CDX2 homeobox gene product expression in neuroendocrine tumors: its role as a marker of intestinal neuroendocrine tumors. Mod Pathol. 2003;17(Suppl 1):101A (abstract).
52. La Rosa S, Rigoli E, Uccella S, et al. CDX2 is a marker of midgut EC-cell tumors and their metastases. Mod Pathol. 2003;17(Suppl 1):105A (abstract).
53. Luckasevic TM, Silverman JF, Medich D, et al. Diagnostic value of CDX-2 expressions in endocrine neoplasms of gastrointestinal origin. Mod Pathol. 2003;17(Suppl 1):106A (abstract).
54. Lloyd RV, Jin L, Qian X, et al. Aberrant p27kip1 expression in endocrine and other tumors. Am J Pathol. 1997;150:461-467.
55. Erickson LA, Jin L, Wollen P, et al. Parathyroid hyperplasia, adenomas, and carcinomas: differential expression of p27kip1 protein. Am J Surg Pathol. 1999;23:288-295. (Pubitemid 29117564)
56. LaRossa S, Sessa F, Capella C, et al. Prognostic criteria in nonfunctioning pancreatic endocrine tumors. Virchows Arch. 1996;429:323-333. (Pubitemid 26421392)
57. Jin L, Qian X, Kulig E, et al. Transforming growth factor-B, transforming growth factor-B receptor II, and p27kip1 expression in nontumorous and neoplastic human pituitaries. Am J Pathol. 1997;151:509-519. (Pubitemid 27330070)
58. His ED, Zuckerberg LR, Yang WI, et al. Cyclin D1/PRAD1 expression in parathyroid adenomas: an immunohistochemical study. J Clin Endocrinol Metab. 1996;81:1736-1739.
59. Erickson LA, Jin L, Goellner JR, et al. Pathologic features, proliferative activity and cyclin D1 expression in Hurthle cell neoplasms of the thyroid. Mod Pathol. 2000;13:186-192. (Pubitemid 30109107)
60. Thapar K, Scheithauer BW, Kovacs D, et al. p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions. Neurosurgery. 1996;38:763-770.
61. Donghi R, Longoni A, Pilotti S, et al. Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. J Clin Invest. 1993;91:1753-1760. (Pubitemid 23127381)
62. Dobashi Y, Sugimura H, Sakamota A, et al. Stepwise paraticipation of p53 gene mutation during dedifferentiation of human thyroid carcinomas. Diagn Mol Pathol. 1994;3:9-14. (Pubitemid 24064788)
63. Rosai J, Carcangui ML, DeLellis RA. Atlas of Tumor Pathology: Tumors of the Thyroid Gland. Washington, DC: Armed Forces Institute of Pathology, 1992.
64. Lloyd RV, Blaivas M. Wilson BS. Distribution of chromogranin and S100 protein in normal and abnormal adrenal medullary tissues. Arch Pathol Lab Med. 1985;109:633-635. (Pubitemid 15233240)
65. Kimura N, Nakazato Y, Nagura H, et al. Expression of intermediate filaments in neuroendocrine tumors. Arch Pathol Lab Med. 1990;114:506-510. (Pubitemid 20147436)
66. Fraga M, Garcia-Caballero T, Antunez J, et al. A comparative immunohistochemical study of phaeochromocytomas and paragangliomas. Histol Histopathol. 1993;8:429-436. (Pubitemid 23252865)
67. Moreno AM, Castilla-Guerra L, Martinez-Torres MC, et al. Expression of neuropeptides and other neuroendocrine markers in human phaeochromocytomas. Neuropeptides. 1999;33:159-163. (Pubitemid 29254079)
68. Terzolo M, Ali A, Pia A, et al. Cyclic Cushing's syndrome due to ectopic ACTH secretion by an adrenal pheochromocytoma. J Endocrinol Invest. 1994;17:869-874.
69. Alvarez P, Isidro L, Gonzalez-Martin M, et al. Ectopic adrenocroticotropic hormone production by a noncatecholamine secreting pheochromocytoma. J Urol. 2002;167:2514-2515. (Pubitemid 34533159)
70. Stefaneanu L, Sasano H, Kovacs K. (eds). Molecular and Cellular Endocrine Pathology. Arnold, London, 2000.
71. Ramsay JA, Asa SL, van Nostrand AW, et al. Lipid degeneration in pheochromocytomas mimicking adrenal cortical tumors. Am J Surg Pathol. 1987;11:480-486. (Pubitemid 17085834)
72. Unger PD, Cohen JM, Thung SN, et al. Lipid degeneration in a pheochromocytoma histologiclly mimicking an adrenal cortical tumor. Arch Pathol Lab Med. 1990;114:892-894. (Pubitemid 20233234)
73. Haak HR, Fleuren GJ. Neuroendocrine differentiation of adrenocortical tumors. Cancer. 1995;75:860-864.
74. Miettinen M. Neuroendocrine differentiation in adrenocortical carcinoma. New immunohistochemical findings supported by electron microscopy. Lab Invest. 1992;66:169-174.
75. Munro LM, Kennedy A, McNicol AM. The expression of inhibin/activin subunits in the human adrenal cortex and its tumours. J Endocrinol. 1999;161:341-347. (Pubitemid 29244262)
76. Arola J, Liu J, Heikkila P, et al. Expression of inhibin alpha in the human adrenal gland and adrenocortical tumors. Endocr Res. 1998;24:865-867. (Pubitemid 29016491)
77. Pelkey Tj. Frierson HF, Jr., Mills SE, Stoler MH. The alpha subunit of inhibin in adrenal cortical neoplasia. Mod Pathol. 1998;11:516-524.
78. Busam KJ, Iversen K, Coplan KA, et al. Immunoreactivity for A103, an antibody to melan-A (Mart-1), in adrenocortical and other steroid tumors. Am J Surg Pathol. 1998;22:57-63. (Pubitemid 28016752)
79. Loy TS, Phillips RW, Linder CL. A103 immunostaining in the diagnosis of adrenal cortical tumors: an immunohistochemical study of 316 cases. Arch Pathol Lab Med. 2002;126:170-172. (Pubitemid 34136632)
80. Schroder S, Padberg BC, Achilles E, et al. Immunocytochemistry in adrenocortical tumours: a clinicomorphological study of 72 neoplasms. Virchows Arch Pathol Anat Histopathol. 1992;420:65-70.
81. Tartour E, Caillou B, Tenenbaum F, et al. Immunohistochemical study of adrenocortical carcinoma. Predictive value of the D11 monoclonal antibody. Cancer. 1993;72:3296-3303. (Pubitemid 23356776)
82. Unger PD, Hoffman K, Thung SN, et al. HMB-45 reactivity in adrenal pheochromocytomas. Arch Pathol Lab Med. 1992;116:151-153.
83. Caya JG. HMB-45 reactivity in adrenal pheochromocytomas. Arch Pathol Lab Med. 1994;118:1169.
84. Busam KJ, Jungbluth AA. Melan-A, a new melanocytic differentiation marker. Adv Anat Pathol. 1999;6:12-28.
85. Jungbluth AA, Busam KJ, Gerald WL, et al. A103: An anti-melan-a monoclonal antibody for the detection of malignant melanoma in paraffin-embedded tissues. Am J Surg Pathol. 1998;22:595-602. (Pubitemid 28213747)
86. Amerigo J, Roig J, Pulido F, et al. Primary malignant melanoma of the adrenal gland. Surgery. 2000;127:107-111. (Pubitemid 30053698)
87. Fornes P, Lesourd A, Dupuis G, et al. [Hyalinized trabecular adenoma of the thyroid gland. Histologic and immunohistochemical study. Report of 2 cases] Arch Anat Cytol Pathol. 1990;38:203-207.
88. Hirokawa M, Carney JA, Ohtsuki Y. Hyalinizing trabecular adenoma and papillary carcinoma of the thyroid gland express different cytokeratin patterns. Am J Surg Pathol. 2000;24:877-881. (Pubitemid 30366277)
89. Lloyd RV. (ed). Endocrine Pathology: Differential Diagnosis and Molecular Advances. Humana Press, Totowa, New Jersey, 2004.
90. Beltrami CA, Barbatelli G, Criante P, et al. An immunohistochemical study in thyroid cancer. Appl Pathol. 1987;5:229-245. (Pubitemid 17144137)
91. Collins G, Maiorana A, Fano RA, et al. Medullary carcinoma of the thyroid gland with sustentacular cell-like cells in a patient with multiple endocrine neoplasia, type IIA. Report of a case with ultrastructural and immunohistochemical studies. Arch Pathol Lab Med. 1994;118:1041-1044. (Pubitemid 24317296)
92. Ferlito A, Friedmann I. Contribution of immunohistochemistry in the diagnosis of neuroendocrine neoplasms of the larynx. J Otorhinolaryngol Relat Spec. 1991;53:235-244.
93. Solcia E, Kloppel G, Sobin LH. Histologic typing of endocrine tumours. In: WHO. International Histological Classification of Endocrine Tumors. New York: Springer-Verlag; 2000.
94. Bishop AE, Power RF, Polak JM. Markers for neuroendocrine differentiation. Pathol Res Pract. 1988;183:119-128.
95. Gould V, Linnoila I, Memoli V, et al. Neuroendocrine components of the bronchopulmonary tract: Hyperplasia, dysplasia, and neoplasia. Lab Invest. 1983;49:519-537. (Pubitemid 14248254)
96. Hammar S. Neuroendocrine neoplasms of the lung. In: Dail D, Hammar S, eds. Pulmonary Pathology. New York: Springer-Verlag; 1993:1207-1258.
97. Tsutsumi Y. Immunohistochemical analysis of neuroendocrine substances in nonneoplastic lung and in neuroendocrine lung tumors. In: Lechago J, Kameya T, eds. Endocrine Pathology Update. New York: Field & Wood; 1990:189-213.
98. Travis W, Linnoila R, Tsokos M, et al. Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. An ultrastructural, immunohistochemical, and flow cytometric study of 35 cases. Am J Surg Pathol. 1991;15:529-553.
99. Sheppard M. Neuroendocrine differentiation in lung tumours. Thorax. 1991;46:843-850.
100. Costes V, Marty-Ane C, Picot M, et al. Typical and atypical bronchopulmonary carcinoid tumors: A clinicopathologic and Ki-67 labeling study. Hum Pathol. 1995;26:740-745.
101. Chen H, Nicoll TL, Zeigler MA, et al. Hurthle cell neoplasms of the thyroid: are there factors predictive of malignancy? Ann Surg. 1998;227:542-546. (Pubitemid 28363271)
102. Krueger JE, Maitra A, Albores-Saavedra J. Inherited medullary microcarcinoma of the thyroid: a study of 11 cases. Am J Surg Pathol. 2000;24:853-858. (Pubitemid 30366273)
103. Ozkara SK, Gurbuz Y, Muezzinoglu B, et al. Encapsulated cystic papillary variant of medullary carcinoma of thyroid gland. Endocr Pathol. 2002;13:167-171. (Pubitemid 34828140)
104. Huss LJ, Mendelson G. Medullary carcinoma of the thyroid gland: an encapsulated variant resembling the hyalinizing trabecular (paraganglioma-like) adenoma of thyroid. Mod Pathol. 1990;3:581-585.
105. Shmid KW, Fischer-Colbrie R, Hagn C, et al. Chromogranin A and B and secretogranin II in medullary carcinomas of the thyroid. Am J Surg Pathol. 1987;11:551-556. (Pubitemid 17097027)
106. Gould VE, Wiedenmann B, Lee I, et al. Synaptophysin expression in neuroendocrine neoplasms as determined by immunocytochemistry. Am J Pathol. 1987;126:243-257. (Pubitemid 17033850)
107. Johannsen L, Daa Schroder H, Schifter S. Calcitonin gene-related peptide and calcitonin in MEN-2 and sporadic pheochromocytomas: an immunohistochemical study. Henry Ford Hosp Med J. 1987;35:115-117. (Pubitemid 18009997)
108. Steenbergh PH, Hoppener JW, Zandberg J, et al. Calcitonin gene related peptide coding sequence is conserved in the human genoma and is expressed in medullary thyroid carcinoma. J Clin Endocrinol Metab. 1984;59:358-360. (Pubitemid 14053666)
109. Baloch ZW, LiVolsi VA. Neuroendocrine tumors of the thyroid gland. Am J Clin Pathol. 2001;111(Suppl):S56-S67.
110. Saad MF, Ordonez NG, Guido JJ, et al. The prognostic value of calciftnin immunostaining in medullary carcinoma of the thyroid. J Clin Endocrinol Metab. 1984;59:1594-1598.
111. Zajac JD, Penschow J, Mason T, et al. Identification of calcitonin and calcitonin gene-related peptide messenger ribonucleic acid in medullary thyroid carcinomas by hybridization histochemistry. J Clin Endocrinol Metab. 1986;62:1037-1043. (Pubitemid 16106737)
112. Lloyd RV. Use of molecular probes in the study of endocrine diseases. Hum Pathol. 1987;18:1199-1211. (Pubitemid 18018948)
113. Talerman A, Lindeman J, Kievit-Tyson PA, et al. demonstration of calcitonin and carcinoembryonic antigen (CEA) in medullary carcinoma of the thyroid (MCT) by immunoperoxidasse technique. Histopathology. 1979;3:503-510. (Pubitemid 10201562)
114. DeLellis RA, Rule AH, Spiler I, et al. Calcitonin and carcinoembryonic antigen as tumor markers in medullary thyroid carcinoma. Am J Clin Pathol. 1978;70:587-594. (Pubitemid 9047252)
115. Lloyd RV, Sisson JC, Marangos PJ. Calcitonin, carcinoembryonic antigen and neuron-specific enolase in medullary thyroid carcinoma. Cancer. 1983;51:2234-2239. (Pubitemid 13058771)
116. Wilson NW, Pambakian H, Richardson TC, et al. Histopathology. 1986;10:815-829.
117. Dasovic-Knezevic M, Bormer O, Holm R, et al. Carcinoembryonic antigen in medullary thyroid carcinoma: an immunohistochemical study applying six novel monoclonal antibodies. Mod Pathol. 1989;2:610-617.
118. Scopsi L, Ferrari C, Pilotti S, et al. Immunocytochemical localization and identification of prosomatostatin gene products in medullary carcinoma of human thyroid gland. Hum Pathol. 1990;21:820-830. (Pubitemid 20250566)
119. Sikri KL, Varndell IM, Hamid QA, et al. Medullary carcinoma of the thyroid. An immunocytochemical and histochemical study of 25 cases using eight separate markers. Cancer. 1985;56:2481-2491. (Pubitemid 16202447)
120. Sundler F, Alumets J, Hakanson R, et al. Somatostatin-immunoreactive cells in medullary carcinoma of the thyroid. Am J Pathol. 1977;88:381-386. (Pubitemid 8168835)
121. Yamada Y, Ito S, Matsubara Y, et al. Immunohistochemical demonstration of somatostatin-containing cells in the human, dog, and rat thyroids. Tohoku J Exp Med. 1977;122:87-92. (Pubitemid 8111429)
122. Matsubayashi S, Yanaihara C, Ohkubo M, et al. Gastrin-releasing peptide immunoreactivity in medullary thyroid carcinoma. Cancer. 1984;53:2472-2477. (Pubitemid 14102489)
123. Sunday ME, Wolfe JF, Roos BA, et al. Gastrin-releasing peptide gene expression in developing hyperplastic and neoplastic human thyroid C-cells. Endocrinology. 1988;122:1551-1558. (Pubitemid 18091990)
124. Yamaguchi K, Abe K, Adachi I, et al. Concomitant production of immunoreactive gastrin-releasing peptide and calcitonin in medullary carcinoma of the thyroid. Metabolism. 1984;33:724-727. (Pubitemid 14061350)
125. Birkenhager JC, Upton GV, Seldenrath HJ, et al. Medullary thyroid carcinoma: ectopic production of peptides with ACTH-like, corticotrophin- releasing factor-like and prolactin production-stimulating activities. Acta Endocrinol (Copenh). 1976;83:280-292.
126. Ohashi M, Yanase T, Fujio N, et al. Alpha neoendorphin-like immunoreactivity in medullary carcinoma of the thyroid. Cancer. 1987;59:277-280. (Pubitemid 17232888)
127. Roth KA, Bensch KG, Hoffman AR. Characterization of opioid peptides in human thyroid medullary carcinoma. Cancer. 1987;59:1594-1598. (Pubitemid 17060102)
128. Uribe M, Fenoglio-Preiser CM, Grimes M, et al. Medullary carcinoma of the thyroid gland. Clinical, pathological, and immunohistochemical features with review of the literature. Am J Surg Pathol. 1985;9:577-594. (Pubitemid 16220659)
129. Mendelsohyn G, Eggleston JC, Weisburger WR, et al. Calcitonin and histaminase in C-cell hyperplasia and medullary thyroid carcinoma. A light microscopic and immunohistochemical study. Am J Pathol. 1978;92:35-52. (Pubitemid 8380707)
130. Colomer A, Martinez-Mas JV, Matias-Guiu X, et al. Sex-steroid hormone receptors in human medullary thyroid carcinoma. Mod Pathol. 1996;9:68-72. (Pubitemid 26061130)
131. Bell CD, Vidal S, Kovacs K, et al. An immunohistochemical survey of nine cases of medullary carcinoma of thyroid including reactivity for Cox-1 and Cox-2 enzymes. Endocr Pathol. 2002;13:331-340.
132. Kim SJ, Lee JH, Yoon JS, et al. Immunohistochemical expression of COX-2 in thyroid nodules. Korean J Intern Med. 2003;18:225-229.
133. Haynik DM, Prayson RA. Immunohistochemical expression of cyclooxygenase-2 (COX-2) in follicular carcinomas of the thyroid. Mod Pathol. 2003;17(Suppl 1):104A (abstract).
134. Ito Y, Yoshida H, Nakano K, et al. Cyclooxygenase-2 expression in thyroid neoplasms. Histopathology. 2003;42:492-497. (Pubitemid 36605593)
135. Bloomer CW, Kenyon L, Hammond E, et al. Cyclooxygenase-2 (COX-2) and epidermal growth factor receptor (EGFR) expression in human pituitary macroadenomas. Am J Clin Oncol. 2003;26:75-80.
136. Erickson LA, Papotti M, Volante M, et al. Merkel cell carcinomas: expression of S-phase kinase-associated protein 2 (Skp2), p27, and proliferation markers. Endocr Pathol. 2003;14:221-229. (Pubitemid 37346703)
137. Eusebi V, Capella C, Cossu A, et al. Neuroendocrine carcinoma within lymph nodes in the absence of a primary tumor, with special reference to Merkel cell carcinoma. Am J Surg Pathol. 1972;16:658-666.
138. Solcia E, Kloppel G, Capella C. Tumors of the endocrine pancreas. In: Rosai J, Sobin LH, eds. Tumors of the Pancreas. Atlas of Tumor Pathology, 3rd ed. Washington, DC: Armed Forces Insitutue of Pathology; 1997;145-132.
139. Morohoshi T, Kanda M, Horie A, et al. Immunocytochemical markers of uncommon pancreatic tumors. Acinar cell carcinoma, pancreatoblastoma and solid-cystic (papillary-cystic) tumor. Cancer. 1987;59:739-747. (Pubitemid 17018750)
140. Klimstra DS, Wenig BM, Adair CF, et al. Pancreatoblastoma. A clinicopathologic study and review of the literature. Am J Surg Pathol. 1995;19:1371-1389.
141. Nauck M, Creutzfeldt W. Insulin producing tumors and the insulinoma syndrome. In: Dayal Y, ed. Endocrine Pathology of the Gut and Pancreas. Boca Raton: CRC Press; 1991;195-226.
142. Solcia E, Capella C, Buffa R, et al. Antigenic markers of neuroendocrine tumors: their diagnostic and prognostic value. In: Fenoglio CM, Weinstein RS, Kaufman N, eds. New concepts in neoplasia as applied to diagnostic pathology. Baltimore: Williams and Wilkins; 1986:242-61.
143. Kloppel G, Heitz PhU. Pancreatic endocrine tumors. Path Res Pract. 1988;183:155-168.
144. Mukai K, Greider MH, Grottin JC, et al. Retrospective study of 77 pancreatic endocrine tumors using the immunoperoxidase method. Am J Surg Pathol. 1982;6:387-399. (Pubitemid 12044737)
145. Clark ES, Carney JA. Pancreatic islet cell tumor associated with Cushing's syndrome. Am J Surg Pathol. 1984;8:917-924. (Pubitemid 15161467)
146. Perkins PL, McLeod MK, Fukuuchi A, et al. Analysis of gastrinomas by immmunohistochemistry and in situ hybridization histochemistry. Diagn Mol Pathol. 1992;1:155-164.
147. Corrin B, Gilby ED, Jones NF, Patrick J. Oat cell carcinoma of the pancreas with ectopic ACTH secretion. Cancer. 1973;31:1523-7.
148. Hobbs RD, Stewart AF, Ravin ND, et al. Hypercalcemia in small cell carcinoma of the pancreas. Cancer. 1984;53:1552-1554. (Pubitemid 14166571)
149. Dollinger MR, Ratner LH, Shamoian CA, et al. Carcinoid syndrome associated with pancreatic tumors. Arch Intern Med. 1967;120:575-580.
150. Gordon DL, Lo MC, Schwartz MA. Carcinoid of the pancreas. Am J Med. 1971;51:412-415.
151. Sanno N, Tahara S, Kurotani R, et al. Cytochemical and molecular biological aspects of teh pituitary and pituitary adenomas - cell differentiation and transcription factors. Prog Histochem Cytochem. 2001;36:263-299.
152. Miettinen M, Karkkainen P. Differentiatl reactivity of HBME-1 and CD15 antibodies in benign and malignant thyroid tumours: preferential reactivity with malignant tumours. Virchows Arch. 1996;429:213-219. (Pubitemid 26402663)
153. Casey MB, Lohse CM, Lloyd RV. Distinction between papillary thyroid hyperplasia and papillary thyroid carcinoma by immunohistochemical staining for cytokeratin 19, galectin-3, and HBME-1. Endocrine Pathology. 2003;14:55-60. (Pubitemid 36605683)
154. Xu XC, El-Naggar AK, Lotan R. Differential expression of galectin-1 and galectin-3 in thyroid tumors: potential diagnostic implications. Am J Pathol. 1995;147:815-822.
155. Bartolazzi A, Gasbarri A, Papotti M, et al. Thyroid Cancer Study Group. Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions. Lancet. 2001;357:1644-1650. (Pubitemid 32568236)
156. Fernandez PL, Merino MJ, Gomez M, et al. Galectin-3 and laminin expression in neoplastic and non-neoplastic thyroid tissue. J Pathol. 1997;181:80-86. (Pubitemid 27099778)
157. Kawachi K, Matsushita Y, Yonezawa S, et al. Galectin-3 expression in various thyroid neoplasms and its possible role in metastasis formation. Hum Pathol. 2000;31:428-433. (Pubitemid 30262863)
158. Orlandi F, Saggiorato E, Pivano G, et al. Galectin-3 is a presurgical marker of human thyroid carcinoma. Cancer Res. 1998;58:3015-3020. (Pubitemid 28335081)
159. Hermann ME, LiVolsi VA, Pasha TL, et al. Immunohistochemical expression of Galectin-3 in benign and malignant thyroid lesions. Arch Pathol Lab Med. 2002;126:710-713.
160. Saggiorato E, Cappia S, De Giuli P, et al. Galectin-3 as a presurgical immunocytodiagnostic marker of minimally invasive follicular thyroid carcinoma. J Clin Endocrinol Metab. 1998;86:2637-2641.
161. Eng C. RET proto-oncogene in the development of human cancer. J Clin Oncol. 1999;17:380-393. (Pubitemid 29022417)
162. Santoro M, Carlomagno F, Hay ID, et al. RET oncogene activation in human thyroid neoplasms is restricted to the papillary carcinoma subtype. J Clin Invest. 1992;89:1517-1522.
163. Santoro M, Sabino N, Ishizaka Y, et al. Involvement of RET oncogene in human tumours: specificity of RET activation to thyroid tumours. Br J Cancer. 1993;68:460-464. (Pubitemid 23258446)
164. Kroll TG, Sarraf P, Pecciarini L, et al. PAX8-PPARgamma1 fusion oncogene in human thyoid carcinoma. Science. 2000;289:1357-1360. (Pubitemid 30656054)
165. Tallini G, Santoro M, Helie M, et al. RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes. Clin Cancer Res. 1988;4:278-294.
166. Cheung CC, Carydis B, Ezzat S, et al. Analysis of RET/PTC gene rearrangments refines the fine needle aspiration diagnosis of thyroid cancer. Clin Endocrinol Metabol. 2001;86:2187-2190. (Pubitemid 32472938)
167. Nikiforova MN, Biddinger PW, Caudill CM, et al. PAX8-PPARgamma rearrangement in thyroid tumors: RT-PCR and immunohistochemical analyses. Am J Surg Pathol. 2002;26:1016-1023. (Pubitemid 34810562)